Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 125, Issue 6
February 5 2015
Issue Cover

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
Stem cell maintenance: aMPLe splicing choices
Stephanie Halene,Diane S. Krause
View Articletitled, Stem cell maintenance: aMPLe splicing choices
INSIDE BLOOD COMMENTARY
Serum cytokines in follicular lymphoma
Eva Kimby
View Articletitled, Serum cytokines in follicular lymphoma
INSIDE BLOOD COMMENTARY
Insights into platelet P2Y12 receptor activation
Robert A. Nicholas
View Articletitled, Insights into platelet P2Y<sub>12</sub> receptor activation
INSIDE BLOOD COMMENTARY
Cytokine-free rapid red cell regeneration
Nadim Mahmud,Donald Lavelle
View Articletitled, Cytokine-free rapid red cell regeneration
INSIDE BLOOD COMMENTARY
VWF and complement
Bernhard Lämmle
View Articletitled, VWF and complement
INSIDE BLOOD COMMENTARY
DGKE disruption ditches complement and drives p38 signaling
K. Vinod Vijayan
View Articletitled, <em>DGKE</em> disruption ditches complement and drives p38 signaling

BLOOD SPOTLIGHT

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Clinical Trials & Observations
Peter Valent,Emir Hadzijusufovic,Gerit-Holger Schernthaner,Dominik Wolf,Delphine Rea,Philipp le Coutre
View Articletitled, Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Supplemental data

HOW I TREAT

How I treat type 2 variant forms of von Willebrand disease
Clinical Trials & Observations
Alberto Tosetto,Giancarlo Castaman
View Articletitled, How I treat type 2 variant forms of von Willebrand disease

CLINICAL TRIALS AND OBSERVATIONS

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
Clinical Trials & Observations
David T. Yeung,Michael P. Osborn,Deborah L. White,Susan Branford,Jodi Braley,Alan Herschtal,Michael Kornhauser,Samar Issa,Devendra K. Hiwase,Mark Hertzberg,Anthony P. Schwarer,Robin Filshie,Christopher K. Arthur,Yiu Lam Kwan,Judith Trotman,Cecily J. Forsyth,John Taper,David M. Ross,Jennifer Beresford,Constantine Tam,Anthony K. Mills,Andrew P. Grigg,Timothy P. Hughes,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group,for the Australasian Leukaemia and Lymphoma Group
View Articletitled, TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
Supplemental data
Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study
Clinical Trials & Observations
Matthew Kang,Majed Alahmadi,Sonja Sawh,Michael J. Kovacs,Alejandro Lazo-Langner
View Articletitled, Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia
Iléana Antony-Debré,Vladimir T. Manchev,Nathalie Balayn,Dominique Bluteau,Cécile Tomowiak,Céline Legrand,Thierry Langlois,Olivia Bawa,Lucie Tosca,Gérard Tachdjian,Bruno Leheup,Najet Debili,Isabelle Plo,Jason A. Mills,Deborah L. French,Mitchell J. Weiss,Eric Solary,Remi Favier,William Vainchenker,Hana Raslova
View Articletitled, Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia
Supplemental data
Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl
Nan Xiao,Suparna Laha,Shankar P. Das,Kayla Morlock,Jonathan L. Jesneck,Glen D. Raffel
View Articletitled, Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl

IMMUNOBIOLOGY

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b
Lorenz Jahn,Pleun Hombrink,Chopie Hassan,Michel G. D. Kester,Dirk M. van der Steen,Renate S. Hagedoorn,J. H. Frederik Falkenburg,Peter A. van Veelen,Mirjam H. M. Heemskerk
View Articletitled, Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b
Supplemental data

LYMPHOID NEOPLASIA

An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup
Clinical Trials & Observations
Fong Chun Chan,Adele Telenius,Shannon Healy,Susana Ben-Neriah,Anja Mottok,Raymond Lim,Marie Drake,Sandy Hu,Jiarui Ding,Gavin Ha,David W. Scott,Robert Kridel,Ali Bashashati,Sanja Rogic,Nathalie Johnson,Ryan D. Morin,Lisa M. Rimsza,Laurie Sehn,Joseph M. Connors,Marco A. Marra,Randy D. Gascoyne,Sohrab P. Shah,Christian Steidl
View Articletitled, An <em>RCOR1</em> loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup
Supplemental data
Identification of CD34+ and CD34− leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia
Yuki Aoki,Takashi Watanabe,Yoriko Saito,Yoko Kuroki,Atsushi Hijikata,Masatoshi Takagi,Daisuke Tomizawa,Mariko Eguchi,Minenori Eguchi-Ishimae,Akiko Kaneko,Rintaro Ono,Kaori Sato,Nahoko Suzuki,Saera Fujiki,Katsuyoshi Koh,Eiichi Ishii,Leonard D. Shultz,Osamu Ohara,Shuki Mizutani,Fumihiko Ishikawa
View Articletitled, Identification of CD34<sup>+</sup> and CD34<sup>−</sup> leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia
Supplemental data
Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment
Marzenna Blonska,Yifan Zhu,Hubert H. Chuang,M. James You,Kranthi Kunkalla,Francisco Vega,Xin Lin
View Articletitled, Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment
Supplemental data
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Muhammad A. Mir,Matthew J. Maurer,Steven C. Ziesmer,Susan L. Slager,Thomas Habermann,William R. Macon,Brian K. Link,Sergei Syrbu,Thomas Witzig,Jonathan W. Friedberg,Oliver Press,Michael LeBlanc,James R. Cerhan,Anne Novak,Stephen M. Ansell
View Articletitled, Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Supplemental data
Genetic inactivation of TRAF3 in canine and human B-cell lymphoma
Kevin R. Bushell,Yukyoung Kim,Fong Chun Chan,Susana Ben-Neriah,Andrew Jenks,Miguel Alcaide,Daniel Fornika,Bruno M. Grande,Sarah Arthur,Randy D. Gascoyne,Christian Steidl,Ryan D. Morin
View Articletitled, Genetic inactivation of <em>TRAF3</em> in canine and human B-cell lymphoma
Supplemental data

PLATELETS AND THROMBOPOIESIS

Identification of a new dysfunctional platelet P2Y12 receptor variant associated with bleeding diathesis
Anna Lecchi,Cristina Razzari,Silvia Paoletta,Arnaud Dupuis,Lea Nakamura,Philippe Ohlmann,Christian Gachet,Kenneth A. Jacobson,Barbara Zieger,Marco Cattaneo
View Articletitled, Identification of a new dysfunctional platelet P2Y<sub>12</sub> receptor variant associated with bleeding diathesis
Dynamin 2–dependent endocytosis is required for normal megakaryocyte development in mice
Markus Bender,Silvia Giannini,Renata Grozovsky,Terese Jönsson,Hilary Christensen,Fred G. Pluthero,Amy Ko,Ann Mullally,Walter H. A. Kahr,Karin M. Hoffmeister,Hervé Falet
View Articletitled, Dynamin 2–dependent endocytosis is required for normal megakaryocyte development in mice

RED CELLS, IRON, AND ERYTHROPOIESIS

A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor
Eyayu Belay,Chris P. Miller,Amanda N. Kortum,Beverly Torok-Storb,C. Anthony Blau,David W. Emery
View Articletitled, A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor
Supplemental data

THROMBOSIS AND HEMOSTASIS

von Willebrand factor is a cofactor in complement regulation
Brief Report
Shuju Feng,Xiaowen Liang,Michael H. Kroll,Dominic W. Chung,Vahid Afshar-Kharghan
View Articletitled, von Willebrand factor is a cofactor in complement regulation
Supplemental data

VASCULAR BIOLOGY

Loss of DGKε induces endothelial cell activation and death independently of complement activation
Sarah Bruneau,Mélanie Néel,Lubka T. Roumenina,Marie Frimat,Lætitia Laurent,Véronique Frémeaux-Bacchi,Fadi Fakhouri
View Articletitled, Loss of DGKε induces endothelial cell activation and death independently of complement activation
Supplemental data

BLOOD WORK

Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy
Yair Herishanu,Ben-Zion Katz
View Articletitled, Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy

ERRATA

Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014;124(3):334-343.
View Articletitled, Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. <em>Blood.</em> 2014;124(3):334-343.
Köffel R, Meshcheryakova A, Warszawska J, et al. Monocytic cell differentiation from band-stage neutrophils under inflammatory conditions via MKK6 activation. Blood. 2014;124(17):2713-2724.
View Articletitled, Köffel R, Meshcheryakova A, Warszawska J, et al. Monocytic cell differentiation from band-stage neutrophils under inflammatory conditions via MKK6 activation. <em>Blood</em>. 2014;124(17):2713-2724.
All Issues

Advertisement intended for health care professionals

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma
Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation
Prothrombotic Antibodies Targeting the Spike Protein's Receptor-Binding Domain in Severe COVID-19
The Contribution of the Monocyte‐Macrophage Lineage to Immunotherapy Outcomes

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals